The CYP3A biomarker 4&bgr;‐hydroxycholesterol does not improve tacrolimus dose predictions early after kidney transplantation

No abstract is available for this paper.

• Publication year

  2017

• Venue

  British Journal of Clinical Pharmacology

• Publication date

  2017-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/bcp.13248PMID 28146606PMCID PMC5465334
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Response to: ‘Response to: Bodyweight‐adjustments introduce significant correlations between CYP3A metrics and tacrolimus clearance’

  2017cited by this paper
• The CYP3A biomarker 4&bgr;‐hydroxycholesterol does not improve tacrolimus dose predictions early after kidney transplantation

  2017cited by this paper
• Population Pharmacokinetic Modelling and Bayesian Estimation of Tacrolimus Exposure: Is this Clinically Useful for Dosage Prediction Yet?

  2016cited by this paper
• 4β-hydroxycholesterol correlates with dose but not steady-state concentration of carbamazepine: indication of intestinal CYP3A in biomarker formation?

  2016cited by this paper
• Comparative performance of oral midazolam clearance and plasma 4β-hydroxycholesterol to explain interindividual variability in tacrolimus clearance.

  2016cited by this paper
• Clinical determinants of calcineurin inhibitor disposition: a mechanistic review

  2016cited by this paper
• Dosing algorithms for initiation of immunosuppressive drugs in solid organ transplant recipients

  2015cited by this paper
• Kidney Transplant Recipients Carrying the CYP3A4*22 Allelic Variant Have Reduced Tacrolimus Clearance and Often Reach Supratherapeutic Tacrolimus Concentrations

  2015cited by this paper
• The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands

  2015cited by this paper
• Progressive decline in tacrolimus clearance after renal transplantation is partially explained by decreasing CYP3A4 activity and increasing haematocrit.

  2015cited by this paper
• The Concise Guide to PHARMACOLOGY 2015/16: Enzymes

  2015cited by this paper
• Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing

  2015cited by this paper
• Improved Tacrolimus Target Concentration Achievement Using Computerized Dosing in Renal Transplant Recipients—A Prospective, Randomized Study

  2015cited by this paper
• OPTN/SRTR 2012 Annual Data Report: Kidney

  2014cited by this paper
• Improved prediction of tacrolimus concentrations early after kidney transplantation using theory-based pharmacokinetic modelling

  2014cited by this paper
• Significant increase in plasma 4β-hydroxycholesterol concentration in patients after kidney transplantation

  2013cited by this paper
• Lessons From Routine Dose Adjustment of Tacrolimus in Renal Transplant Patients Based on Global Exposure

  2013cited by this paper
• The CYP3A4*22 allele affects the predictive value of a pharmacogenetic algorithm predicting tacrolimus predose concentrations.

  2013cited by this paper
• Importance of hematocrit for a tacrolimus target concentration strategy

  2013cited by this paper
• Prediction-Corrected Visual Predictive Checks for Diagnosing Nonlinear Mixed-Effects Models

  2011cited by this paper
• A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients.

  2011cited by this paper
• 4β-Hydroxycholesterol, an endogenous marker of CYP3A4/5 activity in humans.

  2011cited by this paper
• Does the Long Plasma Half‐Life of 4β‐Hydroxycholesterol Impact Its Utility as a Cytochrome P450 3A (CYP3A) Metric?

  2010cited by this paper
• Multi-site Analytical Evaluation of the Abbott ARCHITECT Tacrolimus Assay

  2009cited by this paper
• The Challenge of Achieving Target Drug Concentrations in Clinical Trials: Experience From the Symphony Study

  2009cited by this paper
• 4beta-hydroxycholesterol as an endogenous marker for CYP3A4/5 activity. Stability and half-life of elimination after induction with rifampicin.

  2009cited by this paper
• 4beta-hydroxycholesterol as a marker of CYP3A4 inhibition in vivo - effects of itraconazole in man.

  2009cited by this paper
• Plasma 4β‐Hydroxycholesterol: An Endogenous CYP3A Metric?

  2009cited by this paper
• Importance of Shrinkage in Empirical Bayes Estimates for Diagnostics: Problems and Solutions

  2009cited by this paper
• 4&bgr;-Hydroxycholesterol is a new endogenous CYP3A marker: relationship to CYP3A5 genotype, quinine 3-hydroxylation and sex in Koreans, Swedes and Tanzanians

  2008cited by this paper
• Clinical Pharmacokinetics and Pharmacodynamics of Tacrolimus in Solid Organ Transplantation

  2004cited by this paper
• Models for time-varying covariates in population pharmacokinetic-pharmacodynamic analysis.

  2004cited by this paper
• Decrease in oral bioavailability of ciclosporin by intravenous pulse of methylprednisolone succinate in rats

  2004cited by this paper
• Time-Related Clinical Determinants of Long-Term Tacrolimus Pharmacokinetics in Combination Therapy with Mycophenolic Acid and Corticosteroids

  2004cited by this paper
• Metabolism of 4β-Hydroxycholesterol in Humans*

  2002cited by this paper
• Mechanisms of Clinically Relevant Drug Interactions Associated with Tacrolimus

  2002cited by this paper
• Metabolism of 4 beta -hydroxycholesterol in humans.

  2002cited by this paper
• Antiepileptic drugs increase plasma levels of 4beta-hydroxycholesterol in humans: evidence for involvement of cytochrome p450 3A4.

  2001cited by this paper
• CYP3A genetics in drug metabolism

  2001cited by this paper
• Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes.

  2000cited by this paper
• The disposition of 14C-labeled tacrolimus after intravenous and oral administration in healthy human subjects.

  1999cited by this paper
• Xpose--an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM.

  1999cited by this paper
• Dexamethasone modulation of multidrug transporters in normal tissues

  1999cited by this paper
• Factors affecting the pharmacokinetics of tacrolimus in the first year after renal transplantation. European Tacrolimus Multicentre Renal Study Group.

  1998cited by this paper
• Pharmacokinetics of tacrolimus in liver transplant patients

  1995cited by this paper
• Clinical Pharmacokinetics of Tacrolimus

  1995cited by this paper

• Tacrolimus—why pharmacokinetics matter in the clinic

  2023cites this paper
• Novel Approaches to Characterize Individual Drug Metabolism and Advance Precision Medicine

  2023cites this paper
• Correlations between 4β-hydroxycholesterol and hepatic and intestinal CYP3A4: protein expression, microsomal ex vivo activity, and in vivo activity in patients with a wide body weight range

  2022cites this paper
• Impact of type 2 diabetes on in vivo activities and protein expressions of cytochrome P450 in patients with obesity

  2022cites this paper
• Short‐ and long‐term effects of body weight loss following calorie restriction and gastric bypass on CYP3A‐activity – a non‐randomized three‐armed controlled trial

  2021cites this paper
• Model-informed precision dosing to optimise immunosuppressive therapy in renal transplantation.

  2021cites this paper
• 4β‐Hydroxycholesterol as an Endogenous Biomarker for CYP3A Activity: Literature Review and Critical Evaluation

  2019cites this paper
• Relationships between concomitant biologic DMARDs and prednisolone administration and blood tacrolimus exposure or serum CYP3A4/5-related markers in rheumatoid arthritis patients.

  2019cites this paper
• Effects of Maribavir on P‐Glycoprotein and CYP2D6 in Healthy Volunteers

  2019cites this paper
• Kuypers and Vanhove reply to ‘Was 4β‐hydroxycholesterol ever going to be a useful marker of CYP3A4 activity?’ by Neuhoff and Tucker

  2018influential citation
• Elevated 4β‐hydroxycholesterol/cholesterol ratio in anorexia nervosa patients

  2018cites this paper
• Drug-metabolizing enzymes CYP3A as a link between tacrolimus and vitamin D in renal transplant recipients: is it relevant in clinical practice?

  2018cites this paper
• Population Pharmacokinetics of Tacrolimus in Transplant Recipients: What Did We Learn About Sources of Interindividual Variabilities?

  2018cites this paper
• Comparison of CYP3A4-Inducing Capacity of Enzyme-Inducing Antiepileptic Drugs Using 4&bgr;-Hydroxycholesterol as Biomarker

  2018cites this paper
• Response to: ‘Response to: Bodyweight‐adjustments introduce significant correlations between CYP3A metrics and tacrolimus clearance’

  2017cites this paper
• The CYP3A biomarker 4&bgr;‐hydroxycholesterol does not improve tacrolimus dose predictions early after kidney transplantation

  2017cites this paper
• Pretransplant 4&bgr;‐hydroxycholesterol does not predict tacrolimus exposure or dose requirements during the first days after kidney transplantation

  2017cites this paper
• 4&bgr;‐Hydroxycholesterol level significantly correlates with steady‐state serum concentration of the CYP3A4 substrate quetiapine in psychiatric patients

  2017cites this paper
• Recovery of CYP3A Phenotype after Kidney Transplantation

  2017cites this paper
• Short-­­and­long-­term­effects­of­body­weight­loss­following­ calorie­restriction­and­gastric­bypass­on­CYP3A-­activity­–­­a­ non-­randomized­three-­armed­controlled­trial

  year unknowncites this paper